Keyphrases
Duchenne muscular Dystrophy
100%
Dystrophin
73%
Antisense Oligonucleotides
45%
Exon Skipping
40%
Mouse Model
33%
Myostatin
30%
Antisense
25%
Phosphorodiamidate Morpholino Oligomers
23%
Mdx Mice
23%
Facioscapulohumeral muscular Dystrophy
23%
Double Homeobox
21%
Exon
20%
Skipping
19%
Oculopharyngeal muscular Dystrophy
18%
Gene Therapy
16%
Skeletal muscle
15%
Muscle Pathology
14%
Knockdown
13%
Reading Frame
13%
Clinical Trials
12%
Fibrosis
11%
Neurofibromatosis Type I
10%
Neurofibromatosis Type 1 (NF-1)
10%
Antisense Therapeutics
10%
Pre-mRNA
10%
Muscular Dystrophy
9%
RNA Splicing
9%
Therapeutic Strategies
9%
Dystrophin Gene
9%
Exondys 51
9%
Muscle Mass
8%
Cardiac muscle
8%
ACTA1
8%
Diaphragm muscle
7%
Antisense Therapy
7%
Human muscle
7%
Dystrophic Mice
7%
Oligonucleotide Sequence
7%
Morpholino Oligomers
7%
Periostin (POSTN)
7%
Exon 17
7%
Comparative Analysis
7%
Golodirsen
7%
Splicing Modulation
7%
Muscle Wasting
7%
Muscle Atrophy
7%
Genetic Disease
7%
Muscle Strength
7%
Therapeutic Approaches
6%
Upstream Open Reading Frame (uORF)
6%
Biochemistry, Genetics and Molecular Biology
Dystrophin
63%
Antisense
51%
Oligonucleotide
37%
Exon Skipping
32%
Exon
31%
Morpholino
25%
Gene Therapy
19%
Mouse Model
18%
Skeletal Muscle
16%
Reading Frame
16%
Clinical Trial
14%
Myostatin
12%
Messenger RNA
10%
Adeno Associated Virus Vector
10%
Animal Model
9%
Genetics
9%
RNA Splicing
9%
Open Reading Frame
8%
C-Terminus
7%
Transgene
7%
Homeobox
7%
Periostin
7%
Nucleotide Sequence
7%
Precursor mRNA
6%
Muscle Function
6%
RNA
6%
Genome Editing
6%
Genetic Disorder
5%
Downregulation
5%
Signal Transduction
5%
Gene Inactivation
5%
Adeno Associated Virus
5%
Medicine and Dentistry
Duchenne Muscular Dystrophy
39%
Dystrophin
28%
Exon Skipping
23%
Antisense
21%
Antisense Oligonucleotide
20%
Myostatin
16%
Facioscapulohumeral Muscular Dystrophy
14%
Oculopharyngeal Muscular Dystrophy
14%
Exon
14%
Homeobox
14%
Muscle Atrophy
11%
Gene Therapy
9%
Disease
8%
Messenger RNA Precursor
7%
Genetic Disorder
7%
Antisense Therapy
7%
Muscle Disease
7%
Reading Frame
7%
Neurofibromatosis Type I
7%
Diaphragm Muscle
7%
Histopathology
7%
Oligomer
7%
Clinical Trial
6%
Muscular Dystrophy
6%
Fibrosis
6%
Adeno-Associated Virus
5%
Messenger RNA
5%
Signal Transduction
5%
Gene Inactivation
5%
Morpholino Oligonucleotide
5%